NVP-2 NEW
| Price | $50 | $122 | $213 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: NVP-2 | CAS No.: 1263373-43-8 |
| Purity: 99.76% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | NVP-2 |
| Description | NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9/CycT activity (IC50: 0.514 nM). NVP-2 shows inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases (IC50: 0.584 μM, 0.706 μM, and 0.605 μM, respectively). |
| In vitro | NVP-2 exhibits anti-proliferative activity against leukemia cells, specifically targeting KOPT-K1, Jurkat, P12-ICHIKAWA, DU.528, MOLT 16, HSB-2, PF-382, SKW-3, SUP-T11, DND-41, and HPB-ALL cells with IC50 values of 0.1688 μM, 0.1233 μM, 0.5736 μM, 0.1575 μM, 0.1620 μM, 0.1585 μM, 0.1808 μM, 0.2589 μM, 0.0918 μM, and 0.3023 μM, respectively. NVP-2 (0-10 nM; 72 hours) demonstrates CRBN-dependent anti-proliferative and pro-apoptotic effects in MOLT4 cells (IC50: 9 nM). At 250 nM for 24 hours, NVP-2 induces apoptosis in MOLT4 cells, increasing caspase-3 and γH2A.X expression, although this effect is significantly reduced upon compound washout. Additionally, NVP-2 (250 nM-1 μM; 6 hours) engages CDK9 in both wildtype and CRBN - / - MOLT4 cells without affecting CDK2 and CDK7. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.8 mM), Sonication is recommended. DMSO : 250 mg/mL (487.26 mM), Sonication is recommended. |
| Keywords | NVP-2 | NVP2 | NVP 2 | Leukemia | Inhibitor | inhibit | Cyclin dependent kinase | CRBN | CDK9 | CDK | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Covalent Inhibitor Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $40.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $2500.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $35.00 |
VIP6Y
|
Shanghai UCHEM Inc.
|
2026-07-01 | |
|
Hubei Chuchang Biotech Co., Ltd.
|
2025-03-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY